Interferon beta tied to spike in thrombotic microangiopathy

March 27, 2014
Interferon beta tied to spike in thrombotic microangiopathy

(HealthDay)—There has been an unusually high number of cases of thrombotic microangiopathy associated with severe or malignant hypertension in patients with multiple sclerosis who were receiving therapy with recombinant interferon beta, according to a letter to the editor published in the March 27 issue of the New England Journal of Medicine.

David Hunt, Ph.D., from Edinburgh University in the United Kingdom, and colleagues reviewed case histories and pharmacy records to describe an unexpectedly high number of cases of thrombotic microangiopathy associated with severe or malignant hypertension in four patients with who were receiving therapy with recombinant interferon beta in South Scotland. All patients presented after years of well-tolerated treatment with interferon beta.

The researchers found no genetic or other causal factor for thrombotic microangiopathy, but did note a significant association with a common manufacturing source of interferon beta (Rebif, Merck). Geographical and temporal distribution of the hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura reports shows that very few cases were reported globally in the first nine years of safety monitoring, but that there has been a recent increase in reports from countries that share the same formulation as that used in the United Kingdom.

"We did not detect such patterns or trends in the safety data from a similar recombinant product, suggesting that further investigation of the association with changes in manufacturing may be worthwhile," the authors write.

Explore further: Interleukin 17F level and interferon beta response in patients with multiple sclerosis

More information: Full Text

Related Stories

Interleukin 17F level and interferon beta response in patients with multiple sclerosis

June 3, 2013
A study by Hans-Peter Hartung, M.D., of Heinrich-Heine-Universität, Düsseldoft, Germany, and colleagues examines the association between IL-17F and treatment response to interferon beta-1b among patients with relapsing-remitting ...

Omega-3 fatty acids not associated with beneficial effects in multiple sclerosis: study

April 23, 2012
Omega-3 fatty acid supplements were not associated with beneficial effects on disease activity in patients with relapsing-remitting multiple sclerosis, according to a report of a randomized controlled trial published Online ...

New link found between MS treatment and vitamin D

July 30, 2012
(Medical Xpress) -- A new study by researchers at the Menzies Research Institute Tasmania (Menzies) suggests that one of the main treatments for multiple sclerosis (MS) may also increase the amount of vitamin D patients receive ...

Hepatitis C drug can cause depression

May 1, 2012
There's a high rate of depression among patients with hepatitis C, but a standard treatment for the disease includes a drug, interferon, that can cause depression.

Study revisits first clinical trial to treat multiple sclerosis decades later

April 22, 2011
(Medical Xpress) -- Tracking down nearly all 372 multiple sclerosis patients involved in a pivotal clinical trial of a drug decades ago has allowed a group of researchers from several institutions, led by professors at the ...

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.